It has been reported that activation of the oncogenic EGFR pathway enhances the susceptibility of lung cancers to PD-1 blockade in mouse models, suggesting that combination of PD1 blockade with EGFR TKIs may be a promising therapeutic strategy. This evidence concerns the gene PDCD1 and lung carcinoma.